New Two-in-One drug trial aims to shrink tumors before surgery
NCT ID NCT07286253
Summary
This study is testing whether a new two-in-one immunotherapy drug called QL1706, when given with standard chemotherapy before surgery, can help shrink tumors in women with locally advanced cervical cancer. The goal is to see if this approach leads to better surgical outcomes and reduces the chance of the cancer coming back. It is recruiting 50 women who have not had any prior cancer treatment for their cervical cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOADJUVANT TREATMENT FOR LOCALLY ADVANCED CERVICAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Lipai Chen
RECRUITINGGuangzhou, Guangdong, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.